



Proceedings of the fourth international molecular
pathological epidemiology (MPE) meeting
Citation for published version (APA):
Campbell, P. T., Ambrosone, C. B., Nishihara, R., Aerts, H. J. W. L., Bondy, M., Chatterjee, N., Garcia-
Closas, M., Giannakis, M., Golden, J. A., Heng, Y. J., Kip, N. S., Koshiol, J., Liu, X. S., Lopes-Ramos, C.
M., Mucci, L. A., Nowak, J. A., Phipps, A. I., Quackenbush, J., Schoen, R. E., ... Ogino, S. (2019).
Proceedings of the fourth international molecular pathological epidemiology (MPE) meeting. Cancer
Causes & Control, 30(8), 799-811. https://doi.org/10.1007/s10552-019-01177-z





Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 02 Nov. 2021
Vol.:(0123456789) 
Cancer Causes & Control (2019) 30:799–811 
https://doi.org/10.1007/s10552-019-01177-z
REVIEW ARTICLE
Proceedings of the fourth international molecular pathological 
epidemiology (MPE) meeting
Peter T. Campbell1 · Christine B. Ambrosone2 · Reiko Nishihara3,4,5 · Hugo J. W. L. Aerts6 · Melissa Bondy7 · 
Nilanjan Chatterjee8 · Montserrat Garcia‑Closas9 · Marios Giannakis10,11 · Jeffrey A. Golden12 · Yujing J. Heng13 · 
N. Sertac Kip14 · Jill Koshiol9 · X. Shirley Liu15 · Camila M. Lopes‑Ramos5 · Lorelei A. Mucci16 · Jonathan A. Nowak12 · 
Amanda I. Phipps17 · John Quackenbush5 · Robert E. Schoen18 · Lynette M. Sholl12 · Rulla M. Tamimi16,19 · 
Molin Wang5,16,19 · Matty P. Weijenberg20 · Catherine J. Wu10,11 · Kana Wu4 · Song Yao2 · Kun‑Hsing Yu12,21 · 
Xuehong Zhang19 · Timothy R. Rebbeck10,16 · Shuji Ogino3,11,16,22
Received: 28 September 2018 / Accepted: 27 April 2019 / Published online: 8 May 2019 
© Springer Nature Switzerland AG 2019
Abstract
An important premise of epidemiology is that individuals with the same disease share similar underlying etiologies and 
clinical outcomes. In the past few decades, our knowledge of disease pathogenesis has improved, and disease classification 
systems have evolved to the point where no complex disease processes are considered homogenous. As a result, pathology and 
epidemiology have been integrated into the single, unified field of molecular pathological epidemiology (MPE). Advancing 
integrative molecular and population-level health sciences and addressing the unique research challenges specific to the field 
of MPE necessitates assembling experts in diverse fields, including epidemiology, pathology, biostatistics, computational 
biology, bioinformatics, genomics, immunology, and nutritional and environmental sciences. Integrating these seemingly 
divergent fields can lead to a greater understanding of pathogenic processes. The International MPE Meeting Series fosters 
discussion that addresses the specific research questions and challenges in this emerging field. The purpose of the meeting 
series is to: discuss novel methods to integrate pathology and epidemiology; discuss studies that provide pathogenic insights 
into population impact; and educate next-generation scientists. Herein, we share the proceedings of the Fourth International 
MPE Meeting, held in Boston, MA, USA, on 30 May–1 June, 2018. Major themes of this meeting included ‘integrated 
genetic and molecular pathologic epidemiology’, ‘immunology-MPE’, and ‘novel disease phenotyping’. The key priority 
areas for future research identified by meeting attendees included integration of tumor immunology and cancer disparities 
into epidemiologic studies, further collaboration between computational and population-level scientists to gain new insight 
on exposure-disease associations, and future pooling projects of studies with comparable data.
Peter T. Campbell, Christine B. Ambrosone, Timothy R. Rebbeck 
and Shuji Ogino have contributed equally to this work as the Co-
Chairs of the meeting.
Use of Standardized Official Symbols For unambiguous 
communication, we use HUGO (Human Genome Organisation) 
Gene Nomenclature Committee-approved official symbols 
(or root symbols) for genes, gene products, and gene families, 
including APC, AR, AXIN2, BRAF, CD4, CD8, CTLA4, 
CTNNB1, EGFR, ERBB2, ERG, ESR1, FOXA1, FOXP3, 
HLA, IDH1, IDH2, IGF1, IGF1R, IGFBP, KRAS, MUC1, 
MKI67, PDCD1, PGR, PTEN, RB1, TERT, TMPRSS2, and 
WNT; all of which are described at www.genenames.org. Each 
colloquial name is used in parenthesis following its official 
symbol counterpart. This format enables readers to familiarize 
themselves with the official symbols for genes and gene products 
together with common colloquial names.
Extended author information available on the last page of the article
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BCAC  Breast cancer association consortium
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CDR  Complementarity determining region
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ctDNA  Circulating tumor DNA
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NHS  Nurses’ Health Study
PCR  Polymerase chain reaction
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RTK  Receptor tyrosine kinase
SNP  Single nucleotide polymorphism
TCGA  The Cancer Genome Atlas
TCR  T cell receptor
TMA  Tissue microarray
WCHS  Women’s Circle of Health Study
WCRF  World Cancer Research Fund
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Introduction
A central objective of epidemiology is to investigate why 
some diseases (or related health events) occur in certain 
groups of people but not in others, with the view to apply-
ing that knowledge to prevent or control those outcomes 
in the future. Traditionally in this effort, diseases or health 
events are treated as binary outcomes; for example, a group 
of people either have or do not have cancer at a given organ 
site and, if etiology is of interest, rates of that outcome can 
be compared across levels of a potential exposure. While 
this approach has identified major causes of morbidity and 
mortality in human populations that have subsequently sup-
ported important public health policy changes, the over-sim-
plified ‘yes vs no’ nosology misses the essential concept of 
pathogenic heterogeneity. Most human diseases, and essen-
tially all cancers, are biologically different from one patient 
to the next. Indeed, many human diseases are complex 
processes that occur for reasons that are, in a precise sense, 
unique to that individual, the result of that person’s specific 
host characteristics (e.g., genome) and a multitude of distinct 
external factors (e.g., diet, lifestyle, environmental, micro-
biome). Molecular pathological epidemiology (MPE) is an 
integrative scientific discipline that examines the interplay 
of these unique disease, host, and external factors.
One of the main aims of MPE is to investigate potential 
etiologic/survival factors across strata of molecular charac-
teristics for the disease-of-interest. The underlying premise 
with an etiologic study in MPE is that diseases that share 
certain molecular alterations are more likely to share com-
mon causes; similarly, for prognosis studies, the general 
hypothesis is that some external or endogenous factors may 
influence disease outcomes according to molecular attrib-
utes because those factors likely interact with the diseased 
cells in the local tissue microenvironment. Historically, these 
molecular classifications were often drawn from the clinic, 
such as microsatellite instability (MSI) for colorectal can-
cer and statuses of ESR1 (estrogen receptor 1, ER), PGR 
(progesterone receptor, PR), and ERBB2 (HER-2) for breast 
cancer [1–6]. With the recent growth of high-throughput 
biologic data in large epidemiology studies, disease pheno-
typing has become more sophisticated and includes tumor 
sequencing, gene expression, proteomics, and epigenomics.
The International MPE Meeting Series began in April 
2013 as a small, local meeting of 10 investigators at the Har-
vard School of Public Health. Subsequent meetings became 
larger, with over 150 scientists from more than 16 coun-
tries attending each of the Second (December 2014) [7] and 
Third (May 2016) [8] International MPE meetings. Because 
MPE is inherently transdisciplinary and it is a relatively new 
scientific discipline, these meetings gave attendees a rare 
opportunity to share ideas, methods, successes, and chal-
lenges; further, they were an opportunity to help train the 
next generation of MPE scientists. Herein, we share the pro-
ceedings of the Fourth International Molecular Pathological 
Epidemiology (MPE) Meeting, held in May/June 2018 at 
Dana-Farber Cancer Institute in Boston, MA, USA. A list of 
the speaker names, lecture titles, and key references appears 
in Table 1.
30 May 2018
For the first time in the history of the International MPE 
Meeting Series, a pre-meeting interactive workshop was 
held for current and future leaders in MPE. Dr. Reiko Nishi-
hara chaired the session which included panelists from a 
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Table 1  Summary of podium presentations at the 4th international molecular pathological epidemiology (MPE) meeting in Boston, MA, on 31 
May and 1 June, 2018
Session and speaker name Topic Key references
Integrated genetic, epidemiologic, and tumor analyses, part 1
 Lorelei Mucci Integrating tissue biomarkers into prostate cancer epidemiol-
ogy studies
9–11
 Nilanjan Chatterjee Genetic association testing in the presence of tumor heteroge-
neity
12, 13
 Melissa Bondy Glioma: Insights from molecular epidemiology 14
Integrated genetic, epidemiologic, and tumor analyses, part 2
 Montserrat Garcia-Closas Genetic susceptibility to breast cancer subtypes: implications 
for screening/prevention
12, 13, 15–17
 Rulla Tamimi Leveraging non-tumor tissue sources to understand breast 
cancer etiology
18–21
 Christine Ambrosone Molecular alterations in breast tumor tissues from African 
American women: relationships with risk factors
22–24
Integrated genetic, epidemiologic, and tumor analyses, part 3
 Matty Weijenberg Importance of molecular pathological epidemiology for exam-
ining lifestyle and cancer
25–29
 Timothy Rebbeck Molecular signatures of prostate cancer disparities 30, 31
Immunology and immunotherapy/prevention, part 1
 Shuji Ogino Need for integrative analyses of exposome (including 
microbiome)-tumor-immune interactions
32–38
 X. Shirley Liu Signatures of T cell dysfunction and exclusion predict cancer 
immunotherapy response
39–44
 Robert ‘Rocky’ Schoen Prevention of colorectal adenoma with MUC1 vaccine 45
Immunology and immunotherapy/prevention, part 2
 Catherine Wu Identifying and therapeutically targeting tumor neoantigens 46–49
 Marios Giannakis Genomic mechanisms of immune evasion in colorectal cancer 50–53
Novel disease phenotyping in future medicine and population 
science, part 1
 Jeffrey Golden Computational pathology to precision medicine: a working 
model
54–56
 Lynette Sholl Liquid biopsy for solid tumors: current realities and future 
possibilities
57, 58
 Jan Heng Comparison of pre-processing methods to compute PAM50 
intrinsic subtype in breast cancer and normal tumor-adjacent 
regions
59–61
Novel disease phenotyping in future medicine and population 
science, part 2
 John Quackenbush Using networks to understand the genotype–phenotype con-
nection
62–65
 Hugo Aerts Artificial intelligence in medical imaging 66–69
Special topic lectures
 N. Sertac Kip How solid is a liquid biopsy? 70–75
 Camila Lopes-Ramos Regulatory networks identify sex differences in colon cancer 76
 Molin Wang Addressing sample selection bias due to tissue availability 77
 Song Yao Population differences in breast tumor immune microenviron-
ment between women of African ancestry and European 
ancestry
78–81
 Kun-Hsing Yu Integrating lung cancer omics and histopathology profiles for 
precision medicine
82–86
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wide range of career stages and institutions (Drs Christine 
Ambrosone, Peter Campbell, Montserrat Garcia-Closas, 
Marios Giannakis, John Quackenbush, and Molin Wang). 
The workshop consisted of questions from the session chair 
and audience members with responses from panelists con-
cerning grant writing for transdisciplinary science, trans-
disciplinary team building, and training opportunities. We 
discussed common mistakes in grant applications, devel-
opment of research questions for grants and manuscripts, 
career development of transdisciplinary expertise, areas of 
training that are fundamentally important for trainees to 
pursue MPE research, and tips for successful collaborations 
across disciplines.
30 May 2018
Session 1: Integrated genetic, epidemiologic, 
and tumor analyses #1 (Session Chair: Dr. Peter 
Campbell)
The first speaker of the meeting was Dr. Lorelei Mucci who 
presented an overview of her group’s work on integrating 
tissue biomarkers into prostate cancer epidemiology stud-
ies. She focused on two common molecular subtypes: the 
androgen-regulated gene fusion TMPRSS2:ERG and loss of 
the tumor suppressor PTEN. This work leverages prostate 
tissue biorepositories nested within the Physicians’ Health 
Study (PHS) and Health Professionals Follow-up Study 
(HPFS). The first set of studies focused on the high her-
itability of prostate cancer. Inherited variation within the 
androgen receptor (AR), which regulates AR expression, was 
associated with ERG-positive cancer but not ERG-negative 
disease [9]. Of 39 inherited prostate cancer risk loci, ten 
were differentially associated with risk when stratified by 
ERG status [10]. ERG-positive cancers show higher expres-
sion of the insulin and IGF1 receptors [11]. In unpublished 
data, vigorous physical activity was associated with a sig-
nificantly lower risk of ERG-positive disease, whereas there 
was no association with ERG-negative disease. Finally, use 
of the cholesterol lowering drug, statins, was associated with 
a substantially lower risk of tumors showing PTEN loss. 
These data highlight the etiologic heterogeneity of prostate 
cancer, and the opportunities to elucidate discoveries based 
on integrating tissue biomarkers.
Dr. Nilanjan Chatterjee lectured on the development and 
utility of a broad mixed-effect two-stage logistic regression 
model for discovering new breast cancer germline genetic 
risk loci in the context of tumor heterogeneity [12, 13]. 
Breast cancers are highly heterogeneous, and it may become 
quickly inefficient to evaluate each potential risk locus with 
each different disease sub-type. With genome-wide associa-
tion study (GWAS) data from the Breast Cancer Association 
Consortium (BCAC) that includes nearly 100,000 controls 
and a little over 100,000 cases, approximately 180 SNPs 
were discovered for breast cancer risk overall. When extend-
ing this work to subtype-specific analyses, a two-stage logis-
tic regression approach was preferred over standard analyses 
to account for the large number of comparisons, correlations 
between markers, missing marker data, and other reasons. 
Case–control and case-case odds ratios were calculated 
using the mixed-effect two-stage approach, and 11 novel 
SNPs for subtype-specific breast cancers were identified. 
One of the more interesting findings from this work was the 
discovery that a TP53 SNP was associated with increased 
risk of luminal breast cancer and with decreased risk of tri-
ple negative tumors, probably reflecting the different patho-
logic mechanisms that drive these different tumor sub-types 
and potentially underscoring the broad utility of this statisti-
cal approach.
In the last lecture of the first session, Dr. Melissa Bondy 
spoke about GWAS results for gliomas, overall and when 
stratified by histological and molecular subtypes [14]. Brain 
tumors, which comprise a highly heterogenous group of 
cancers, account for 1–2% of all cancers overall. To bet-
ter understand germline genetic risk factors for glioma, Dr. 
Bondy and collaborators pooled data from eight independ-
ent glioma GWAS datasets. Their combined meta-analysis 
identified 13 novel glioma risk loci (five for glioblastoma 
multiforme (GBM) and eight for non-GBM). Curiously, all 
but one locus showed significant allele frequency differ-
ences between GBM and non-GBM tumors. The only locus 
consistently associated with glioma risk was at 17p13.1 
(TP53). Overall, genetic heritability is estimated to account 
for approximately 1/3 of the population variability in glioma. 
Further work showed a high degree of concordance, accord-
ing to germline genetics, between familial and sporadic glio-
mas, suggesting genetic predisposition is largely the same 
for both types of disease. Many of the risk SNPs were in 
DNA-repair or telomere maintenance-related pathways. 
Future work in this area will include additional, detailed 
work within core pathways, sequencing efforts, and gene-
environment interaction.
Session 2: Integrated genetic, epidemiologic, 
and tumor analyses #2 (Session Chair: Dr. Kana Wu)
The second morning session continued with the earlier 
theme of integrated studies in cancer epidemiology. Dr. 
Montserrat ‘Montse’ Garcia-Closas’s lecture gave an over-
view of recent developments in risk factor identification for 
breast cancer according to clinical subtype and the implica-
tions for those results on personal risk prediction. Breast 
cancer is a heterogenous disease with different survival 
outcomes. The most aggressive tumors are hormone recep-
tor negative tumors, including triple negative tumors that 
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are also negative for ERBB2 (HER2) amplification. These 
phenotypes represent approximately 13% of tumors and are 
more common in younger women and women of African 
descent. GWAS have identified nearly 180 germline loci for 
breast cancer risk overall. More recent work has identified 
clusters of SNPs associated with specific tumor features, 
including ESR-1 status and grade. Dr. Garcia-Closas and 
colleagues have developed Polygenic Risk Scores (PRS) for 
ESR-1 + and ESR-1-negative specific disease and are inte-
grating them into risk models to identify women at different 
risks of breast cancer overall, and by subtypes; however, 
more work on implementation is needed before translating 
these tools into clinical practice [12, 13, 15–17].
Dr. Rulla Tamimi described the role of early life risk fac-
tors on markers in non-tumor tissues. Many risk factors for 
breast cancer in adults occur early in life. More specifically, 
there are windows of susceptibility that may be relevant to 
specific tissue markers of disease processes. Her group has 
conducted work on early life body size in the Nurses’ Health 
Studies (NHS) that asked women about their body size at 
ages 5, 10, and 20. They found that larger body size in early 
life was inversely associated with proliferative benign breast 
disease and breast cancer risk [18–20]. In a study of normal 
breast tissue adjacent to benign breast disease lesions, they 
found women who reported as being heavier early in life 
(ages 5–10) had a reduction of MKI67 (Ki67) expression 
[21]. In additional work, her group has examined breast tis-
sue gene expression in the Nurses’ Health Studies using a 
transcriptome array. In preliminary work, they have seen 
differences in gene expression patterns related to exposures 
when considering tumor and adjacent normal tissue. Dr. 
Tamimi echoed a theme that was common during this year’s 
meeting: the need for more consortia work for validation, 
replication, and new discovery.
Dr. Christine Ambrosone discussed her research focused 
on understanding the etiology of more aggressive breast 
cancers in African American women, particularly tumors 
that do not express ESR1 (estrogen receptor, ER) that are 
associated with poorer prognosis [22]. She described results 
from a study of DNA methylation in tumors from African-
American and European-American women that found that 
methylation of a gene important to guiding the luminal phe-
notype, FOXA1, was greatest in ESR1 (ER)-negative breast 
cancers [23]. Methylation was more common in women who 
had children and did not breastfeed, suggesting a mechanism 
for the increased risk of ESR1 (ER)-negative breast cancer 
with parity, and not breastfeeding [24].
Session 3: Integrated genetic, epidemiologic, 
and tumor analyses #3 (Session Chair: Dr. Song Yao)
After a 2-h pause in podium presentations for attendees to 
interact and to view poster presentations, the afternoon ses-
sions began with the third installment of the integrated epi-
demiology theme.
The first lecture of the afternoon session was presented 
by Dr. Matty Weijenberg who discussed the role of MPE in 
supporting lifestyle guidelines for cancer prevention. She 
illustrated how MPE could contribute to the research direc-
tions provided by the third expert report from the World 
Cancer Research Fund (WCRF)/American Institute for Can-
cer Research (AICR) on diet, nutrition, physical activity, 
and cancer. First, she showed examples of how mutational 
spectra of tumors can provide clues to mechanisms, for 
example how heme iron intake is associated with specific G 
to A mutations in KRAS genes in colorectal tumors, point-
ing to the role of alkylating agents [25]. More recent studies 
suggest that tumor signatures of mutational processes are 
associated with exogenous mutational processes [26]. Sec-
ond, she showed how exposure to the Dutch Hunger Winter 
was associated with a reduced risk of colorectal cancer only 
in tumors with a CpG-island methylator phenotype (CIMP) 
[27] and tumors with increasing number of IGFBP genes 
methylated [28]. Third, she showed how investigating sub-
types of tumors can reveal previously unknown etiologies. 
For example, results from a meta-analysis revealed how 
adherence to a Mediterranean diet is associated specifically 
with a reduced risk of ESR1 (ER)-negative and PGR (PR)-
negative postmenopausal breast cancer [29].
In the final lecture of the ‘integrated epidemiology’ ses-
sions, Dr. Timothy Rebbeck discussed the role of germline 
genetics in explaining some disparities for prostate cancer 
[30, 31]. Prostate cancer has higher incidence and mortal-
ity rates in African American men compared to all other 
race/ethnic groups. Many prostate cancer susceptibility loci 
have been identified via GWAS for prostate cancer overall. 
But the contribution of these loci to prostate cancer dispari-
ties is unclear. To address this issue, Dr. Rebbeck’s group 
evaluated the population structure of 68 previously identi-
fied prostate cancer susceptibility loci by calculating: (1) 
genetic disparity contribution statistics to quantify the con-
tribution of each SNP to differences in prostate cancer risk 
across populations, and (2) genetic risk scores that integrate 
GWAS results with allele frequency data from 45 African 
and 19 non-African populations. They found that predicted 
prostate cancer risks were highest for men of West African 
descent and lowest for men of East Asian descent. These 
population-level differences were further explained by the 
out-of-Africa bottleneck and natural selection. Only a few 
loci seemed to drive the excess prostate cancer risk observed 
in African American men. Although most prostate cancer 
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susceptibility loci are evolving neutrally across different 
race/ethnic groups, there are several instances where alleles 
have hitchhiked at higher frequencies with adaptive alleles, 
including alleles for skin pigmentation (at 2q37).
Session 4: Immunology, immunotherapy, 
and prevention #1 (Session Chair: Dr. Amanda 
Phipps)
The first lecture in the ‘immunology-MPE’ session was 
given by Dr. Shuji Ogino who spoke about the broad impor-
tance of incorporating immune system data into MPE stud-
ies. Despite remarkable advances of cancer immunology in 
recent years, investigations on the influences of the expo-
some on tumor-immune interactions lag. To address a sub-
stantial gap between cancer immunology and epidemiology, 
the integrative field of immunology-MPE can investigate 
influences of the exposome (dietary, lifestyle, environmen-
tal, microbial, pharmacological, and other exposures) on 
tumor-immune interactions [32, 33]. Using epidemiologi-
cal studies and colorectal cancer cases with data on immune 
response, tumor molecular pathology, and tissue microor-
ganisms, proof-of-principle immunology-MPE studies pro-
vide evidence supporting hypotheses that several exposures 
influence carcinogenic processes through their influences on 
tumor-immune interactions [34–38]. For instance, marine 
omega-3 polyunsaturated fatty acid intake has been associ-
ated with a lower risk of colorectal carcinoma containing 
abundant  FOXP3+ cells (mostly regulatory T cells) [34] and 
a prudent dietary pattern has been associated with a lower 
risk of colorectal carcinoma containing abundant Fusobac-
terium nucleatum [38]. These new insights from immunol-
ogy-MPE research can provide a possible path for precision 
immunoprevention and immunotherapy.
Dr. X. Shirley Liu introduced her work in mining and 
integrating large-scale tumor molecular profiles to inform 
cancer immunology and immunotherapy. Dr. Liu discussed 
three algorithms that her laboratory developed to extract use-
ful insights from treatment-naïve RNA-seq samples in The 
Cancer Genome Atlas (TCGA). First, ‘TIMER’ can estimate 
immune cell components in tumors [39], and a webserver 
was created for users to explore immune infiltration across 
TCGA tumors and to draw inferences on user-provided sam-
ples [40]. Second, ‘TRUST’ can assemble T cell receptor 
(TCR) and B cell receptor (BCR) complementarity-deter-
mining regions (CDR3s) from bulk tumor RNA-seq data 
[41]. When applied to over 10,000 samples in the TCGA, 
TRUST assembled 3 M TCR CDR3 sequences from tumor 
RNA-seq samples and revealed associations between tumor 
infiltrating TCR clonotype diversity and tumor mutational 
load [42]. TRUST also identified 30 M BCR sequences from 
TCGA tumor RNA-seq and revealed widespread B cell 
clonal expansions among other events [43] Third, ‘TIDE’ 
software derived gene expression signatures from pretreated 
tumor specimens to predict patient response to anti-PDCD1 
(PD-1) and anti-CTLA4 treatment [44]. TIDE analyses of 
published immune checkpoint inhibitor trials suggested 
some tumors are unlikely to respond to anti-PDCD1 (PD-1) 
or anti-CTLA4 alone. This work indicates that tumor RNA-
seq, even on treatment naïve tumors, is cost-effective to 
inform tumor microenvironment and immunity.
Dr. Robert ‘Rocky’ Schoen described his group’s experi-
ences in developing a vaccine for colorectal cancer. Immu-
notherapy targeting of antigens that are aberrantly expressed 
on colon cancers and polyps offers the potential for rela-
tively non-invasive, non-toxic, and prolonged preventive 
strategies. Whereas vaccines in advanced cancers have had 
little success, likely because of immunosuppressive tumor 
microenvironments, vaccines administered in pre-malignant 
stages when the immune system is still powerful should be 
more effective. Dr. Schoen and colleagues are testing this 
hypothesis using the adenomatous polyp-to-colon-cancer 
pathway. Their target is MUC1, a tumor-associated antigen 
that is abnormally expressed on polyps and colon cancers. In 
a pilot study of 39 patients with a history of advanced adeno-
mas, after a series of 3 injections, almost half of the patients 
showed a twofold ratio increase in anti-MUC1 IgG at week 
12 compared to pre-vaccination levels. A booster injection at 
week 52 resulted in a large increase in IgG, demonstrating a 
persistent T cell memory response [45]. There was minimal 
evidence of toxicity. A double-blind randomized trial of 110 
patients using a similar vaccination protocol is due to report 
in late 2019. That trial will also evaluate a clinical endpoint, 
via assessment of adenoma recurrence.
Session 5: Immunology, immunotherapy, 
and prevention #2 (Session Chair: Dr. Xuehong 
Zhang)
In the final session of the day, Dr. Catherine Wu lectured 
on her work in identifying tumor antigens. Multiple lines of 
evidence demonstrate that tumor neoantigens are an impor-
tant class of immunogenic antigens. Neoantigens arise from 
amino acid changes encoded by somatic mutations in the 
tumor cell. This work has advanced in recent years due to 
the availability of next-generation sequencing approaches 
and the maturation of predictive algorithms [46]. One of 
the central questions of Dr. Wu’s work is: can a personalized 
cancer vaccine stimulate anti-tumor immunity in humans? 
Her group conducted a trial in high-risk melanoma patients. 
They dosed 6 melanoma patients with up to 20 neoantigens 
to test for safety, feasibility, and immune response. Across 
the 6 patients, they observed ~ 20% CD8 and > 60% CD4 
T cell responses against the neoantigens [47], all of which 
were new responses following vaccination. In another 
trial, Dr. Wu and colleagues tested Neovax in patients with 
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glioblastoma multiforme, a tumor with a lower somatic 
mutation rate [48]. Again, they saw circulating neoantigen-
specific responses. Her presentation ended with a series of 
questions that need to be addressed to implement better per-
sonalized immunotherapies, including the identification of 
methods to reduce time from diagnosis to vaccine adminis-
tration [49].
In the final presentation of the day, Dr. Marios Giannakis 
presented work on investigating the genomic mechanisms 
of immune evasion in colorectal cancer. Immune checkpoint 
blockade has shown activity in approximately 50% of MSI-
high colorectal cancers while it is ineffective in microsatel-
lite stable tumors [50, 51]. To better understand the genetic 
drivers of immune evasion in colorectal cancer, Dr. Gian-
nakis and colleagues integrated next generation sequencing 
data from over 1,200 tumors with transcriptional and immu-
nohistochemical measures of immune infiltration. The tumor 
samples for their studies were from TCGA, the NHS, and 
the HPFS [52]. They demonstrated that WNT-signaling and 
immune-related genes were significantly mutated in colo-
rectal cancer. They also found frequent inactivating anti-
gen-presentation machinery mutations in MSI-high tumors, 
and an inverse association between WNT-signaling activity 
and T cell infiltration in all subtypes of colorectal cancer. 
Tumors with biallelic disruptive mutations in APC or with 
AXIN2 super-enhancer hypomethylation had a significantly 
decreased T cell transcriptional signature [53]. In summary, 
this work found evidence of immuno-editing through dis-
ruptive mutations in antigen-presentation machinery, and 
of exclusion of an effective immune response through an 
active WNT-signaling pathway in colorectal cancer. These 
results shed light to the underlying molecular mechanisms 
of immune evasion in this disease.
1 June 2018
The second day of the meeting began with award announce-
ments to trainees and early career investigators.
Session 6: Novel disease phenotyping in future 
medicine and population science #1 (Session Chair: 
Dr. Jonathan Nowak)
The first lecture of the day was given by Dr. Jeffrey Golden 
who first shared a few clinical case reports whereby modern 
tools in molecular pathology aided in more precise diag-
noses and superior treatments for patients and almost cer-
tainly improved their prognoses. Dr. Golden summarized 
the importance of computational pathology [54, 55] into five 
central components: [1] mutation-specific treatment stratifi-
cation, including clinical trial eligibility; [2] better precision 
diagnostics; [3] superior prognostication; [4] better targeted 
therapies, which may be more effective, less toxic, and more 
cost-effective; and [5] new biomarker discovery. One of the 
central challenges for a practicing clinician is in translating 
the abundance of computational data generated by omics 
platforms (e.g., Oncopanel) into tractable information and, 
ultimately, into knowledge of what those mutations mean 
for the benefit of the patient. Dr. Golden’s institution has 
converted these sorts of information into knowledge—that 
is, what mutations in those genes mean to the patient and 
clinician [56]. He used Google maps’ system of layered geo-
spatial databases as an analogy for creating relational data-
bases for patients, based on a multitude of patient (e.g., clini-
cal, omic, pharmacy) and external (e.g., electronic medical 
records, published literature) inputs, that are ultimately led 
back to actionable decisions for clinicians and their patients.
Dr. Lynette Sholl’s lecture focused on recent advance-
ments in liquid biopsy techniques for solid tumors. She 
started with a clinical case report that highlighted some of 
the advantages of liquid biopsies over tumor/solid tissues, 
including: tumor tissues often have limited mass and/or nor-
mal cell contamination; there is often a need to repeat a solid 
tissue biopsy upon relapse; and some tumors are anatomi-
cally inaccessible. Liquid biopsies can look for circulating 
tumor DNA (ctDNA) although their rarity in peripheral 
blood makes the approach challenging. Current and emerg-
ing technologies include commercial allele specific PCR 
platforms, droplet digital PCR (ddPCR), NGS, and electric 
field-based measurements [57]. Investigators at her insti-
tute decided to invest in ddPCR for ctDNA testing in can-
cer patients. Using ddPCR for EGFR and KRAS hotspots, 
they found sensitivity was a direct correlate of the number 
of metastatic sites, owing to the amount of DNA shed into 
circulation. Patients with only 1 metastatic site saw sensi-
tivity levels of approximately 60% whereas patients with 
four or more metastatic sites had nearly 100% sensitivity 
with ddPCR [58]. Ultimately, liquid biopsy may be used in 
detection of early relapse after definitive therapy, minimal 
residual disease testing, or even cancer screening.
Dr. Yujing (Jan) Heng’s talk highlighted the importance 
of gene expression pre-processing methods to obtain reliable 
and reproducible breast cancer molecular subtype classifica-
tion by PAM50. Her work compared two established pre-
processing methods (i.e., modified median gene centering 
[59] and subgroup-specific gene centering [60]) to compute 
molecular subtypes using PAM50 in tumor and tumor-
adjacent tissues from participants in the NHS. She reported 
that although molecular subtypes were highly comparable 
using either method, the subgroup-specific method tends 
to classify more cases into more aggressive subtypes. The 
distribution of molecular subtypes within the NHS/NHS-
II was comparable to other population-based studies, and 
as expected, there were more cancer recurrences in women 
with Basal-like subtype compared to Luminal A subtype. 
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Lastly, she showed that the correlation of molecular sub-
types classified using PAM50 and immunohistochemical 
(IHC) surrogates remain poor and more research is needed 
to refine the IHC definitions to more closely approximate 
PAM50 subtypes [61].
Session 7: Novel disease phenotyping in future 
medicine and population science #2 (Session Chair: 
Dr. Reiko Nishihara)
After a short break, the second session of the day contin-
ued with the ‘novel disease phenotyping’ theme. The first 
lecture of the session was given by Dr. John Quackenbush 
who described his group’s efforts to infer biological net-
works from GWAS and gene expression data. To do this, 
they developed several systems biology algorithms [62, 63]. 
Dr. Quackenbush’s lecture described how these algorithms 
were used to better understand networks of GWAS-identified 
SNPs and gene expression data with outcomes, and how pat-
terns of gene networks differ between phenotypes. Central 
to this work are the hypotheses that biological systems are 
driven by complex networks; the structure of the network 
captures the biology of the system; and, that network struc-
ture is conditional, depending on tissue, biological state, 
and individual. One of the main findings from their work 
is that biological networks are organized into tight commu-
nities such that, in most instances, it is not a single gene 
controlling a single trait, but a family of genetic variants that 
influence a process. They also find disease-associated (i.e., 
GWAS) SNPs map to communities whose genes share func-
tions that are related to the disease, and that most GWAS 
SNPs are not global hubs in the network, but local hubs in 
the network. Overall, their work demonstrates how network 
analysis can take us beyond simple differential expression 
in understanding disease [64, 65].
Dr. Hugo Aerts described his work at the intersection of 
radiology, bioinformatics, and data science. He discussed 
recent work of building Artificial Intelligence (AI) image 
analysis systems to extract a rich radiomics set and used 
these features to build biomarkers [66]. He illustrated how 
technological advances in AI and deep learning are moving 
imaging modalities into the heart of patient care as imaging 
can address a critical barrier in precision medicine because 
solid tumors can be spatially and temporally heterogene-
ous, and the standard approach to tumor sampling, often 
invasive needle biopsy, is unable to fully capture the spatial 
state of the tumor [67, 68]. The main objectives of the talk 
were to learn about the motivation and methodology of AI 
technologies in radiology, to learn about the existing and 
future potential role of radiologic AI with other omics data 
for precision medicine, and to learn about open-source infor-
matics developments [69].
Session 8: Discussion topic special lectures (Session 
Chair: Dr. John Quackenbush)
In the final session for podium presentations, the organizing 
committee selected five submitted abstracts whose topics 
were thought to provide the broadest interest and potential 
to generate discussion for the attendees.
Dr. N Sertac Kip lectured on her work in developing a 
liquid biopsy for tumor detection. Dr. Kip spoke of the limi-
tations to standard tumor profiling (e.g., biopsy/resection), 
including invasiveness, pain, cost, and lack of sensitivity to 
mutations unique to the non-biopsied tissue [70]. Further, 
targeted therapies place tumor cells under selective pressure, 
thereby triggering clonal progression, which can then be 
captured [71]. Liquid biopsy is ideal for comparing pre- and 
post-treatment variants and to optimize sequence of therapy 
[72]. Lung cancer appears to be an ideal tumor site for this 
application. Liquid biopsy measures biomarkers that are pre-
dictive and prognostic for lung cancer [73]. Coming back to 
the title of her talk, “How solid is liquid biopsy?”, only two 
of 34 cases had discordance between solid tumor and liquid 
biopsy measures, indicating that the liquid biopsy is quite 
solid [74]. There are some people with mutations in tissue 
that are not detected in liquid biopsy. Sensitivity also varies 
by tumor type and stage [75]. Research is rapidly evolving 
in this area, but the techniques are not yet suitable for wide 
clinical application and guidelines are currently lacking for 
standardization of the liquid biopsy results.
Dr. Camila Lopes-Ramos spoke about her work in iden-
tifying biological explanations for the higher incidence and 
mortality rates for men than women from colon cancer. Life-
style and serological (i.e., sex steroid hormone) differences 
are often postulated to explain some, but not all, of these 
observed sex differences. The potential molecular features 
that drive sex differences are understudied. Her work used 
both transcript-based and gene regulatory network meth-
ods to analyze RNA-seq data from TCGA for colon cancer. 
They found no meaningful differences between tumors from 
men and women for gene expression. Next, they examined 
patient-specific gene regulatory networks and found consid-
erable sex differences in drug and xenobiotic metabolism via 
cytochrome P450 pathways which were considerably more 
pronounced in women. This finding was replicated in several 
independent study samples. This drug metabolism pathway 
was not associated with survival in men; however, women 
treated with chemotherapy that had increased targeting 
(compared to less targeting) of this pathway had consider-
ably better 10-year overall survival [76]. This network-based 
approach can be applied to explore other etiologic and demo-
graphic differences for cancer and other complex diseases.
Dr. Molin Wang lectured on the problem of sample selec-
tion bias due to tissue availability and solutions to this prob-
lem. Missing data is a common problem for tumor subtype 
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data. This poses severe statistical challenges for MPE 
research because the outcome is missing. She reported the 
percentages of colorectal, breast and ovarian cancer cases 
with missing tumor marker data in representative national 
and international cohort studies and consortia. She intro-
duced the definitions and assumptions of possible missing-
ness patterns of the tumor marker data in the MPE con-
text and used the NHS breast and colorectal cancer data 
to illustrate the problem of sample selection bias in MPE 
research. She then described the statistical methods available 
to explore these issues, such as the complete case analysis 
method, the missing indicator method, inverse probability 
weighting [77], and the multiple imputation method. They 
found that the former two methods could lead to biased esti-
mates and the latter two methods were usually most helpful 
in dealing with the potential selection bias problem. She 
used a colorectal cancer molecular subtype to illustrate these 
methods. She described the possible scenarios when the 
missingness is not at random, and the statistical challenges 
in these scenarios.
Dr. Song Yao presented recent data from his group on 
population differences between women of African American 
descent and European American descent in the breast tumor 
immune microenvironment. Convincing evidence demon-
strates marked differences in systemic immune response 
between African American and European American popu-
lations [78–80], which is also supported in a recent study on 
circulating cytokine levels [81]. However, data are scarce 
on population differences in tumor immune microenviron-
ment. With data from the Women’s Circle of Health Study 
(WCHS), they showed that breast tumors from African 
American women had a significantly stronger presence of 
tumor-infiltrating lymphocytes than breast tumors from 
European American women, independent of tumor histo-
pathological features. Using NanoString immune profiling, 
they confirmed the overall stronger immune infiltration in 
breast tumors from African American women than those 
from European American women, and further showed 
stronger exhausted T cell signatures in tumors from African 
American women. Their data revealed marked population 
differences in tumor immune response, which may contrib-
ute to some of the observed racial disparities in breast cancer 
survival.
Dr. Kun-Hsing Yu lectured about his work on integrating 
lung cancer multi-omics and histopathology images [82]. 
Lung cancer is the most prevalent cancer worldwide, and 
histopathological assessment is indispensable for its diag-
nosis [83]. However, how histopathology findings relate 
to molecular abnormalities remains largely unknown, and 
human evaluation of pathology slides do not accurately pre-
dict prognosis. To address this gap, his group obtained over 
2,100 hematoxylin and eosin stained histopathology whole-
slide images, RNA sequencing, and proteomics data of lung 
adenocarcinoma and squamous cell carcinoma patients from 
TCGA, and nearly 300 additional images from the Stanford 
Tissue Microarray (TMA) Database [84]. They extracted 
nearly 10,000 quantitative image features and used regular-
ized machine-learning methods to select the top features and 
to distinguish shorter-term survivors from longer-term sur-
vivors with stage I adenocarcinoma or squamous cell carci-
noma in the TCGA data set [85]. They successfully validated 
the survival prediction framework with the TMA cohort 
[85], identified the cell-cycle regulation and nucleotide 
binding pathways underpinning tumor cell dedifferentiation 
[86], and built an integrative histopathology-transcriptomics 
model to generate better prognostic predictions for stage I 
adenocarcinoma patients compared with gene expression 
or histopathology studies alone [86]. These results suggest 
that automatically derived image features can predict the 
prognosis of lung cancer patients and therefore contribute 
to precision oncology.
Conclusions
The Fourth International MPE Meeting assembled over 170 
trainees and experts working in the various, diverse scientific 
disciplines that comprise MPE. As even more sophisticated 
means of molecular characterization of disease processes 
enter epidemiologic studies and clinical medicine, the utility 
and preponderance of MPE principles and methods should 
continue to expand. As actively discussed in the Fourth 
International MPE Meeting, new ideas of flexibly shaping 
and integrating multiple disciplines are further expanding 
opportunities in biomedical and population sciences [87]. 
In terms of key recommendations and next steps, integra-
tion of tumor immunology into epidemiologic studies and 
further exploration of disparity research were concluded as 
high priorities for the field. Additionally, further collabora-
tions between computational and population-level scientists 
were noted as high priority as were general pooling projects 
between studies with similar data. We look forward to meet-
ing again at the Fifth International MPE Meeting, tentatively 
planned for June 2020 in Boston, MA, USA.
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